| Literature DB >> 32226935 |
Jia-Hui Li1, Xian-Tao Song1, Xue-Yao Yang1, Wen-Yi Zhang1, Hao-Ran Xing1.
Abstract
OBJECTIVE: To identify risk factors of saphenous vein graft (SVG) failure and to investigate the utility of anatomical SYNTAX score (SS) and SYNTAX score II (SS-II) in predicting SVG failure.Entities:
Keywords: Coronary artery bypass grafting; Graft patency; Predictor; SYNTAX score; Saphenous vein graft
Year: 2019 PMID: 32226935 PMCID: PMC7096321 DOI: 10.1016/j.cdtm.2019.05.005
Source DB: PubMed Journal: Chronic Dis Transl Med ISSN: 2095-882X
Saphenous vein graft patency in anatomical SYNTAX score tertiles (n = 801).
| Time | Total | Anatomical SYNTAX score | |||
|---|---|---|---|---|---|
| Low | Intermediate | High | |||
| 1 year | 75/143 (52.4) | 30/54 (55.6) | 30/58 (51.7) | 15/31 (48.4) | 0.81 |
| 5 years | 250/512 (48.8) | 115/229 (50.2) | 82/167 (49.1) | 53/116 (45.7) | 0.73 |
| 10 years | 345/730 (47.3) | 162/343 (47.2) | 116/239 (48.5) | 67/148 (45.3) | 0.82 |
Data are presented as the number of patent grafts/ the number of follow-up grafts (%).
Saphenous vein graft patency in three groups classified by SYNTAX score II treatment recommendation (n = 598).
| Time | Total | SYNTAX score II treatment recommendation | |||
|---|---|---|---|---|---|
| PCI | PCI or CABG | CABG | |||
| 1 year | 46/110 (41.9) | 3/4 (75.0) | 30/73 (41.1) | 13/33 (39.4) | 0.39 |
| 5 years | 164/390 (42.1) | 3/4 (75.0) | 109/254 (42.9) | 52/132 (39.4) | 0.32 |
| 10 years | 220/549 (40.1) | 3/5 (60.0) | 146/357 (40.9) | 71/187 (38.0) | 0.38 |
Data are presented as the number of patients with patent grafts/the number of follow-up patients (%). PCI: percutaneous coronary intervention; CABG: coronary artery bypass grafting.
Baseline characteristics at the patient level (n=598).
| Characteristics | Without SVG failure ( | With SVG failure ( | |
|---|---|---|---|
| Demographics | |||
| Age, years, mean ± SD | 61.3 ± 8.5 | 61.6 ± 8.9 | 0.630 |
| Men, | 191 (80.6) | 275 (76.2) | 0.200 |
| BMI, kg/m2, mean ± SD | 26.4 ± 3.0 | 26.4 ± 2.9 | 0.910 |
| Presentation, | 0.080 | ||
| Angina | 219 (92.4) | 321 (88.9) | |
| NSTEMI | 18 (7.6) | 36 (10.0) | |
| STEMI | 0 (0) | 4 (1.1) | |
| Years from CABG, years, median (Q1–Q3) | 3.0 (1.0–5.0) | 3.0 (1.0–7.0) | 0.130 |
| Comorbidities, | |||
| Hypertension | 162 (68.4) | 252 (69.8) | 0.710 |
| Diabetes mellitus | 95 (40.1) | 157 (43.5) | 0.410 |
| Cerebral vascular disease | 24 (10.1) | 51 (14.1) | 0.150 |
| Prior myocardial infarction | 72 (30.4) | 112 (31.0) | 0.870 |
| Prior PCI | 55 (23.2) | 64 (17.7) | 0.100 |
| Peripheral vessel disease | 18 (7.6) | 33 (9.1) | 0.510 |
| Smoking, | 0.250 | ||
| Never | 109 (46.0) | 171 (47.4) | |
| Former | 85 (35.9) | 109 (30.2) | |
| Current | 43 (18.1) | 81 (22.4) | |
| Family history, | 20 (8.4) | 24 (6.6) | 0.410 |
| On-pump CABG, | 24 (10.1) | 48 (13.3) | 0.240 |
| Isolated CABG, | 214 (90.3) | 340 (94.2) | 0.080 |
| CABG surgical duration, hours, median (Q1–Q3) | 4.0 (4.0–5.0) | 4.0 (3.5–4.8) | 0.220 |
| Laboratory test | |||
| Creatinine, μmol/L, mean ± SD | 81.2 ± 18.4 | 78.7 ± 18.0 | 0.100 |
| FBG <7.0 μmol/L, | 176 (74.3) | 238 (65.9) | 0.030 |
| UA <360 μmol/L, | 127 (53.6) | 190 (52.6) | 0.890 |
| TG ≥ 1.7 mmol/L, | 89 (37.6) | 151 (41.8) | 0.200 |
| CHOL, mmol/L, median (Q1–Q3) | 3.88 (3.37–4.52) | 3.89 (3.43–4.64) | 0.260 |
| HDL-C, mmol/L, median (Q1–Q3) | 0.95 (0.83–1.12) | 0.96 (0.83–1.12) | 0.950 |
| LDL-C <1.8 mmol/L, | 50 (21.1) | 71 (19.7) | 0.770 |
| Anatomical SYNTAX score, median (Q1–Q3) | 23.0 (17.0–31.0) | 24.0 (15.0–31.0) | 0.790 |
SVG: saphenous vein graft; SD: standard deviation; BMI: body mass index; NSTEMI: non-ST elevation acute myocardial infarction; STEMI: ST elevation acute myocardial infarction; CABG: coronary artery bypass grafting; PCI: percutaneous coronary intervention; FBG: fasting blood glucose; UA: uric acid; TG: triglyceride; CHOL: total cholesterol; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol.
Baseline characteristics at the graft level (n=801).
| Characteristics | Without SVG failure ( | With SVG failure ( | |
|---|---|---|---|
| Demographics | |||
| Age, years, median (Q1–Q3) | 62.0 (56.0–69.0) | 62.0 (56.0–68.0) | 0.600 |
| Men, | 282 (76.8) | 329 (75.8) | 0.730 |
| BMI, kg/m2, mean ± SD | 26.4 ± 3.0 | 26.4 ± 3.0 | 0.750 |
| Years from CABG, years, median (Q1–Q3) | 3.0 (1.0–5.0) | 4.0 (1.0–7.0) | 0.040 |
| Comorbidities, | |||
| Hypertension | 251 (68.4) | 301 (69.4) | 0.770 |
| Diabetes mellitus | 148 (40.3) | 193 (44.5) | 0.240 |
| Cerebral vascular disease | 45 (12.3) | 56 (12.9) | 0.790 |
| Prior myocardial infarction | 103 (28.1) | 130 (30.0) | 0.560 |
| Prior PCI | 78 (21.3) | 70 (16.1) | 0.060 |
| Peripheral vessel disease | 31 (8.4) | 46 (10.6) | 0.300 |
| Smoking, | 0.450 | ||
| Never | 184 (50.1) | 200 (46.1) | |
| Former | 112 (30.5) | 137 (31.6) | |
| Current | 71 (19.3) | 97 (22.4) | |
| On-pump CABG, | 48 (13.1) | 62 (14.3) | 0.620 |
| Isolated CABG, | 333 (90.7) | 408 (94.0) | 0.080 |
| SVG type, | |||
| Independent | 168 (45.8) | 282 (65.0) | <0.001 |
| Sequential | 191 (52.0) | 146 (33.6) | <0.001 |
| Composite | 8 (2.2) | 6 (1.4) | 0.390 |
| Grafting to right coronary system, | 174 (47.4) | 257 (59.2) | <0.001 |
| Laboratory test | |||
| Creatinine, μmol/l, mean ± SD | 80.1 ± 19.2 | 78.5 ± 18.0 | 0.250 |
| FBG <7.0 mmol/L | 269 (73.3) | 287 (66.1) | 0.040 |
| UA <360 μmol/L | 195 (53.1) | 230 (53.0) | 0.950 |
| TG ≥ 1.7 mmol/L | 149 (40.6) | 181 (41.7) | 0.590 |
| CHOL, mmol/L, median (Q1–Q3) | 3.88 (3.40–4.65) | 3.92 (3.45–4.66) | 0.190 |
| HDL-C, mmol/L, median (Q1–Q3) | 0.96 (0.84–1.13) | 0.95 (0.83–1.13) | 0.700 |
| LDL-C <1.8 mmol/L | 75 (20.4) | 80 (18.4) | 0.560 |
| Anatomical SYNTAX Score, median (Q1–Q3) | 23.5 (18.0–31.5) | 24.3 (15.9–31.5) | 0.560 |
SVG: saphenous vein graft; SD: standard deviation; CABG: coronary artery bypass grafting; PCI: percutaneous coronary intervention; FBG: fasting blood glucose; UA: uric acid; TG: triglyceride; CHOL: total cholesterol; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol.
Factors related to patient-level saphenous vein graft failure.
| Variables | Univariable analysis | Multivariable analysis | ||||
|---|---|---|---|---|---|---|
| 95% | 95% | |||||
| Isolated CABG | 1.740 | 0.940–3.221 | 0.078 | Not selected | – | – |
| Total cholesterol | 1.145 | 0.979–1.339 | 0.090 | Not selected | – | – |
| FBG <7.0 mmol/L | 0.664 | 0.456–0.968 | 0.033 | Not selected | – | – |
| Creatinine | 0.992 | 0.983–1.001 | 0.099 | Not selected | – | – |
| Years from CABG (every 5 years added) | 1.067 | 1.017–1.120 | 0.009 | 1.384 | 1.063–1.801 | 0.016 |
OR: odds ratio; CI: confidence interval; CABG: coronary artery bypass grafting; FBG: fasting blood glucose.
Factors related to graft-level saphenous vein graft failure.
| Variables | Univariable analysis | Multivariable analysis | ||||
|---|---|---|---|---|---|---|
| 95% | 95% | |||||
| Prior PCI | 0.713 | 0.498–1.019 | 0.063 | Not selected | – | – |
| FBG <7.0 mmol/L | 0.725 | 0.529–0.992 | 0.044 | Not selected | – | – |
| Total cholesterol | 1.126 | 0.990–1.282 | 0.071 | Not selected | – | – |
| Graft type | ||||||
| Sequential | Reference | – | – | Reference | – | – |
| Independent | 2.196 | 1.647–2.929 | <0.001 | 3.094 | 2.186–4.380 | <0.001 |
| Grafting to the right coronary system | 1.611 | 1.217–2.132 | 0.001 | 2.524 | 1.793–3.554 | <0.001 |
| Years from CABG (every 5 years added) | 1.366 | 1.112–1.678 | 0.003 | 1.282 | 1.026–1.603 | 0.029 |
PCI: percutaneous coronary intervention; FBG: fasting blood glucose; CABG: coronary artery bypass grafting; OR: odds ratio; CI: confidence interval.